在HER2过表达乳腺癌新辅助治疗中使用卡铂继发的肉眼血尿。
Gross hematuria secondary to use of carboplatin in neoadjuvant treatment of breast cancer with HER2 overexpression.
作者信息
Pastorello Julia, da Silva Nicolas Almeida Leal, Schuch Natalia Bassani, Lando Emanuela
机构信息
Department of Clinical Oncology, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil
Academic League of Oncology and Hematology - LAONC - HCPF, Hospital de Clínicas de Passo Fundo - HCPF, Passo Fundo, Rio Grande do Sul, Brazil.
出版信息
BMJ Case Rep. 2022 Sep 6;15(9):e245407. doi: 10.1136/bcr-2021-245407.
Breast cancer is a high prevalent neoplasia in women worldwide, and platinum compounds are widely used to treat it. On rare occasions, macroscopic hematuria associated with carboplatin has been identified. Thus, the present study aims to report a rare case of a female patient diagnosed with invasive ductal carcinoma, which presented hematuria secondary to carboplatin, showing improvement of the condition after 4 days of expectant treatment with clot lavage. Due to the scant description of hematuria secondary to carboplatin in the scientific literature, it is essential to report such case in order to assist and enrich the understanding of this event.
乳腺癌是全球女性中一种高发性肿瘤，铂类化合物被广泛用于治疗乳腺癌。在极少数情况下，已发现与卡铂相关的肉眼血尿。因此，本研究旨在报告一例罕见的女性患者，该患者被诊断为浸润性导管癌，出现了继发于卡铂的血尿，在采用凝块冲洗进行4天的观察治疗后病情有所改善。由于科学文献中对卡铂继发血尿的描述较少，报告此类病例对于帮助和丰富对该事件的认识至关重要。
Zotero 插件